Thursday, April 27, 2023 Study Raises Concerns SARS-CoV-2 Evolution Outpaces Vaccine-Generated Antibodies This transmission electron micrograph shows SARS-CoV-2 virus particles isolated from a patient (NIAID). A NIAID-led Phase 2 trial comparing two Pfizer bivalent mRNA COVID-19 boosters found that while both induced an immune response, neutralizing antibodies were less potent against some of the emerging SARS-CoV-2 variant viruses. This scenario led the researchers – part of the Coronavirus Variant Immunologic Landscape Trial, or COVAIL – to express concern about virus evolution leaving "not optimal" antibody responses that can be addressed with vaccine strain updates. Their study, published in Clinical Infectious Diseases, calls for continuous viral surveillance to assess potential for waning vaccine effectiveness as the virus continues to evolve.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107